Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NextGen Bioscience has acquired use, commercialization and ownership rights of a patent application for the treatment of cancer from Oxon Life Science.
Subscribe to our email newsletter
The patent application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are normally resistant to conventional therapies.
Konstantinos Kardiasmenos, CEO of NextGen, said: “Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies.”